Alwin Schuller
Company: AstraZeneca
Job title: Senior Principal Scientist
Bio:
Alwin has ~20 years’ industry experience mentoring diverse research teams and providing biology and in vivo pharmacology strategy to various small molecule and antibody projects ranging from target validation through clinical development. The past ~7 years he has held various roles at AstraZeneca including bioscience lead of the Arginase program (from inception to candidate selection), the A2AR inhibitor AZD4635, and the MET inhibitor AZD6094 / savolitinib.
Seminars:
Discussion/Q&A 2:30 pm
day: Day One
AZD0011 Shows Immune Activation & Anti-Tumor Activity as Mono- & Combination Therapy in Syngeneic Tumor Models 1:30 pm
Developed a novel arginase inhibitor (AZD0011) able to reverse arginase induced immune suppression in vivo Inhibition of arginase by AZD0011 increases the number and activation of intra-tumoral cytotoxic T-cells and NK cells Arginase inhibitor AZD0011 shows combination activity with various immune-activating strategies including checkpoint inhibitors and TLR agonistsRead more
day: Day One